PEBC key terms

The specific disease or condition for which a medicine is approved and intended to be used, forming the legal and clinical basis for a prescription and for counselling points given to the patient.

A situation, condition, or concurrent medicine in which a drug must not be used because the risk of harm clearly outweighs any possible benefit, requiring the pharmacist to refuse or redirect therapy.

A condition in which a drug should be used with caution, close monitoring, or dose adjustment because harm is possible but not inevitable; the prescriber must weigh benefit against risk before proceeding.

Prescribing an approved medicine for an indication, dose, population, or route not covered by its authorised product labelling, which is often lawful and evidence-based but requires the pharmacist to assess supporting evidence.

The fraction of an administered dose of unchanged drug that reaches the systemic circulation, expressed as a percentage; intravenous dosing is by definition 100%, while oral bioavailability depends on absorption and first-pass metabolism.

The demonstration that two pharmaceutical products containing the same active ingredient release it into the body at a comparable rate and extent, typically shown by comparative plasma concentration studies meeting regulatory confidence limits.

Presystemic elimination of an orally absorbed drug by enzymes in the gut wall and liver before it reaches the systemic circulation, which reduces oral bioavailability and can make oral and intravenous doses non-interchangeable.

An apparent volume relating the amount of drug in the body to its plasma concentration; a large value indicates extensive tissue distribution, while a small value suggests the drug stays largely within the vascular space.

The volume of plasma from which a drug is completely removed per unit time, reflecting combined hepatic, renal, and other elimination pathways; it determines the maintenance dose needed to sustain a target steady-state concentration.

The time required for the plasma concentration of a drug to fall by half during elimination; it governs dosing interval, time to steady state, and how long a drug persists after stopping therapy.

The condition in which drug input equals drug elimination, so plasma concentrations fluctuate around a constant average; it is generally reached after about four to five half-lives of regular dosing.

An initial larger dose given to rapidly achieve a therapeutic plasma concentration when the usual maintenance regimen would take too long, calculated from the volume of distribution and target concentration.

Measuring plasma concentrations of selected drugs with narrow therapeutic ranges and interpreting them alongside timing, adherence, and clinical status to individualise dosing and avoid toxicity or treatment failure.

A property of drugs whose effective and toxic concentrations lie close together, so small changes in dose, formulation, or interacting drugs can cause treatment failure or serious toxicity and demand careful monitoring.

A clinically significant alteration in a drug's effect caused by another medicine, food, supplement, or disease state, acting through pharmacokinetic mechanisms such as enzyme changes or pharmacodynamic mechanisms such as additive toxicity.

Reduced activity of drug-metabolising enzymes, often by a competing substrate, leading to slower clearance and higher plasma concentrations of affected drugs; the effect develops quickly and can cause toxicity.

Increased synthesis or activity of drug-metabolising enzymes after repeated exposure to an inducing agent, lowering concentrations and effects of co-administered substrates; the effect develops over days to weeks and resolves slowly.

A harmful or unintended response to a medicine at doses normally used for prevention, diagnosis, or treatment, ranging from predictable dose-related effects to unpredictable immune-mediated reactions.

The systematic submission of suspected harmful medicine effects to a national pharmacovigilance authority, which supports signal detection and regulatory action; health professionals are expected to report serious or unexpected reactions.

The science and activities relating to detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems, encompassing spontaneous reporting, signal evaluation, and risk-management activities throughout a product's lifecycle.

A structured process of obtaining and comparing a patient's complete medication list across care transitions, resolving discrepancies, and communicating an accurate list to the next care provider to prevent errors.

A comprehensive medication list obtained using multiple sources, including patient interview and at least one reliable secondary source such as a pharmacy record, forming the foundation for reconciliation and safe prescribing decisions.

Any preventable event that may cause or lead to inappropriate medication use or patient harm, occurring at prescribing, transcribing, dispensing, administration, or monitoring stages of the medication-use process.

Pairs of medicine names or packaging that appear or sound similar and are easily confused, a recognised source of wrong-drug errors that pharmacists mitigate through careful reading, separation, and verification.

A risk-reduction convention in which parts of easily confused medicine names are written in capital letters to highlight differences, helping prescribers and dispensers distinguish similar products during ordering and checking.

The clinical judgement that two products with the same active ingredient, strength, and dosage form can be expected to produce the same therapeutic effect when used in the same patient under the same conditions.

The regulatory and professional determination that one product may be substituted for another in practice, based on evidence of comparable safety, efficacy, and quality, often supported by bioequivalence data.

The conscientious use of the best available research evidence, combined with clinical expertise and patient values, to guide decisions about the care of individual patients rather than relying on habit or anecdote.

Systematically developed statements that summarise evidence and recommend care for specific clinical circumstances, used by pharmacists to evaluate prescribing appropriateness and to support recommendations to prescribers.

The study of how the body handles a drug over time, described by absorption, distribution, metabolism, and excretion; these processes determine the concentration-time profile used to design dosing regimens.

The study of what a drug does to the body, including receptor binding, signal transduction, and the relationship between drug concentration and the intensity of therapeutic or toxic effects.

A communication technique in which the pharmacist deliberately attends to the patient's words and feelings and reflects them back to confirm understanding, encouraging disclosure of concerns and improving the accuracy of information gathered.

A question phrased to invite a descriptive answer rather than yes or no, used at the start of a patient interview to uncover the full story, beliefs, and concerns before narrowing to specific closed questions.

A technique in which the patient explains in their own words how they will take a medicine or manage a condition, allowing the pharmacist to verify understanding and correct misunderstandings rather than merely asking whether everything is clear.

A person's ability to obtain, understand, and act on health information; limited literacy affects medicine use and safety, so pharmacists adjust language, use plain words, and confirm comprehension.

A structured, interactive discussion in which the pharmacist provides tailored information about a medicine, verifies the patient's understanding, and addresses concerns so that the patient can use therapy safely and effectively.

The extent to which a patient takes medicines as agreed with the prescriber, encompassing initiation, correct timing and dose, and persistence; it is assessed non-judgementally and improved through shared problem-solving.

A collaborative, goal-oriented conversation style that strengthens a patient's own motivation and confidence for change by exploring ambivalence and eliciting the patient's reasons rather than advising or persuading.

A process in which the pharmacist or prescriber presents evidence-based options and the patient's values and preferences are integrated into the chosen plan, supporting informed consent and commitment to therapy.

A patient's voluntary agreement to a treatment or service after receiving and understanding relevant information about benefits, risks, and alternatives, documented as part of ethical and legally sound practice.

The professional and legal duty to protect a patient's personal health information from unauthorised disclosure, permitting sharing only with consent or where required by law or imminent serious harm.

Statutes governing the collection, use, and disclosure of personal health information, setting rules on consent, access, retention, and breach notification that shape how pharmacy records and communications are managed.

The activities a pharmacist is legally authorised and competent to perform, such as prescribing in some jurisdictions or administering injections, defined by legislation, regulation, and professional standards.

The level and quality of care that a reasonably competent practitioner would provide in similar circumstances, used to judge professional conduct and to guide decisions when a situation is uncertain.

The obligation of a pharmacist to accept responsibility for their decisions and actions, practise within competence, disclose errors, and place patient welfare above commercial or personal interests.

A situation in which a personal, financial, or other secondary interest could improperly influence professional judgement; it must be recognised, disclosed, and managed to preserve patient trust.

A documented, individualised plan listing a patient's identified drug therapy problems, goals, interventions, and monitoring parameters, with responsibilities and timelines, used to coordinate and evaluate pharmaceutical care.

Any undesirable event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes, such as an untreated indication, inappropriate drug, or adverse effect requiring intervention.

A planned re-contact with the patient to assess response, adherence, and adverse effects after an intervention, confirming whether goals were met and prompting further adjustment of the care plan.

Directing a patient to another health professional or service when the presenting problem exceeds the pharmacist's competence or scope, accompanied by relevant information and clear communication of the reason.

Interprofessional teamwork in which pharmacists, physicians, nurses, and others share responsibility for patient care through agreed roles, communication, and mutual respect, often supported by formal agreements.

A structured handover format covering Situation, Background, Assessment, and Recommendation, used when contacting prescribers to convey a concern concisely and to propose a clear course of action.

The contemporaneous written record of a pharmacist's assessment, recommendations, interventions, and follow-up plans, providing accountability, continuity of care, and legal evidence of professional practice.